New York, Jan 22, 2026, 15:23 EST — Regular session
- GRAIL shares surged roughly 13% in afternoon trading, hitting a new intraday peak
- Investors are zeroing in on the company’s cash burn and its growth goals for 2026
- Upcoming catalysts feature an FDA submission window plus multiple clinical readouts expected by mid-year
Shares of GRAIL (GRAL.O) surged 13.2% to $114.41 Thursday afternoon, topping out at an intraday high of $118.50 earlier in the session.
This shift is critical now since GRAIL is at a point where minor shifts in adoption and cash flow can rapidly alter forecasts. The company markets Galleri, a multi-cancer early detection blood test — a screening tool that still depends heavily on wider reimbursement and regulatory approval.
Traders are focusing more on near-term indicators: how quickly Galleri volumes can rise without a matching surge in spending, and if GRAIL can maintain its regulatory timeline through spring.
In a Jan. 12 filing tied to an investor presentation, GRAIL shared preliminary 2025 forecasts along with a more conservative 2026 spending outlook. The company projected 2025 revenue between $147 million and $148 million, and expected to end the year with $904 million in cash. It also announced a sharp drop in cash burn, from $579 million in 2024 down to $274 million in 2025. For 2026, GRAIL predicted Galleri revenue growth of 22% to 32%, aimed to keep cash burn below $300 million, and highlighted a cash “runway” extending into 2030. SEC
The presentation also highlighted a modular PMA submission slated for the first quarter — PMA being the FDA’s premarket approval process — and flagged bigger clinical updates expected by mid-2026. These include full results from the 35,000-participant PATHFINDER 2 study and the 140,000-participant NHS-Galleri trial.
GRAIL has been flagging the FDA filing as a critical milestone for months. CEO Bob Ragusa noted in a November earnings release that the company expects to wrap up its PMA submission for Galleri in the first quarter of 2026.
Investors have been watching closely as the company expands into new markets, focusing on outside funding and partnerships. Last year, Samsung and GRAIL announced that Samsung C&T and Samsung Electronics would invest $110 million in equity, with the deal set to close in early 2026. The two are also collaborating to introduce Galleri to parts of Asia.
But the situation goes both ways. A delay in the FDA timeline, disappointing clinical results, or sluggish adoption by health systems could tank the stock fast—especially if payers remain hesitant to back widespread screening tests.
Investors are now focused on whether GRAIL will wrap up the modular PMA filing in Q1 and clear the final hurdles related to the Samsung deal. An October SEC document tied to that transaction mentioned definitive collaboration agreements aimed for completion by Jan. 31, 2026.
Related articles: Biotechnology
